about
Structure and function of steroid receptor AF1 transactivation domains: induction of active conformationsA new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule.Functional probing of the human glucocorticoid receptor steroid-interacting surface by site-directed mutagenesis. Gln-642 plays an important role in steroid recognition and bindingA new strategy for selective targeting of progesterone receptor with passive antagonists.Early aldosterone action: toward filling the gap between transcription and transport.Two panels of steroid receptor luciferase reporter cell lines for compound profiling.A critical role of helix 3-helix 5 interaction in steroid hormone receptor functionBiochemical mechanisms of drug action: what does it take for success?Familial Multiplicity of Estrogen Insensitivity Associated With a Loss-of-Function ESR1 Mutation.The decrease of mineralcorticoid receptor drives angiogenic pathways in colorectal cancer.Chemical neuroimmunology: health in a nutshell bidirectional communication between immune and stress (limbic-hypothalamic-pituitary-adrenal) systems.Mineralocorticoid receptor mutations and a severe recessive pseudohypoaldosteronism type 1.Aspects to Consider in Adopting Pregnancy-Specific Reference Intervals.Three-dimensional modeling of and ligand docking to vitamin D receptor ligand binding domainHelix 3-helix 5 interactions in steroid hormone receptor functionStructural and functional relationships of the steroid hormone receptors' N-terminal transactivation domainFinerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1.Controlled tubulogenesis from dispersed ureteric bud-derived cells using a micropatterned gel.Ligand-selective potentiation of rat mineralocorticoid receptor activation function 1 by a CBP-containing histone acetyltransferase complex.Glucocorticoids increase VE-cadherin expression and cause cytoskeletal rearrangements in murine brain endothelial cEND cells.Dexamethasone induces the expression of metalloproteinase inhibitor TIMP-1 in the murine cerebral vascular endothelial cell line cEND.Glucocorticoid effects on mouse microvascular endothelial barrier permeability are brain specific.Occludin as direct target for glucocorticoid-induced improvement of blood-brain barrier properties in a murine in vitro system.Distinct interaction of cortivazol with the ligand binding domain confers glucocorticoid receptor specificity: cortivazol is a specific ligand for the glucocorticoid receptor.Characterization of a prolactin gene polymorphism and its associations with systemic lupus erythematosus.Conformation of the mineralocorticoid receptor N-terminal domain: evidence for induced and stable structure.Targeted oncogenesis reveals a distinct tissue-specific utilization of alternative promoters of the human mineralocorticoid receptor gene in transgenic mice.Homology modelling of the ligand binding domain of mineralocorticoid receptor: close structural kinship with glucocorticoid receptor ligand binding domain and their similar binding mode with DOC (de-oxy corticosterone).Ligand selectivity by nuclear hormone receptors.Histone deacetylase inhibition, but not a mineralocorticoid receptor antagonist spironolactone, attenuates atypical transcription by an activating mutant MR (MRS 810L ).
P2860
Q24537137-801AF3BD-6CB4-4F51-8573-2360DDDF1ED1Q24604026-F0BFDD77-9E8C-4DEF-8E2F-444CB1EA631AQ28375155-2913A5B2-64AB-4FC7-B112-061AFDDC3E20Q33633141-6113EA71-74CF-4291-9DF2-8D23969241BDQ33731974-4586127E-D755-4A61-B19C-C8C423ABCB76Q33837335-9A63AD27-FA1D-4C07-BC91-6FBCF6AC983EQ33864134-E3A99919-45C2-4761-98D4-5C7C0299BEF1Q34344862-93EDA7A3-1D60-4807-98C3-75460188EF4EQ34542890-B5F3E620-AE73-4810-A666-4A7C5F0F7C62Q34651210-913C0BFD-D909-475F-B44E-736147A96D2DQ35148867-6C4DF81F-AB3B-43EB-A6F9-2BEB59D87FC6Q35758441-B99C92BE-F346-4F54-9A55-FA176E3987C7Q36551065-4BC6CCD3-8818-4B05-A8E0-CC63B6039230Q37104516-F286DD26-55E7-4EF2-BEA2-AC270454A8EEQ37148537-932B6B63-CDEB-4D3D-A060-994A5CB0C63AQ37576700-00C93448-76E7-40DD-B6E0-9272D38C5BE6Q38850114-DEBDC6D0-69D2-4B1E-91F0-409AEF2712C1Q39029115-9E25AD34-37CE-40BF-ADDC-465185D6027EQ39674733-391CDCAB-1831-4760-B963-9360DB0858B9Q40019129-F0A78194-7475-4118-B4F4-A53C222FC609Q40167696-C0800E9B-1192-4F3E-87ED-0F81058DBABAQ40303548-C5B1B31C-72CE-411F-8F2C-FCEE2D93E7D2Q40442621-5348CF7C-EC4C-4994-8797-8955C2649993Q40763783-39CDE874-7E83-456B-8758-53C61CDF3F10Q40773545-58181377-213C-4A86-B673-99E394CF65CCQ42289640-B3132C26-4D3A-491C-AF31-310ADCE3B722Q43583255-C4058A8B-1BDD-4F2E-BDEE-07C316E70662Q44080467-18D22DEF-402E-4FE1-99C3-BD40A34E5C6DQ47742955-9FB2AE61-1FCE-4B3F-9595-DC1693A36356Q47866992-E63DB11F-D37A-4297-B852-76BE610E08D9
P2860
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
Antagonism in the human mineralocorticoid receptor.
@en
Antagonism in the human mineralocorticoid receptor.
@nl
type
label
Antagonism in the human mineralocorticoid receptor.
@en
Antagonism in the human mineralocorticoid receptor.
@nl
prefLabel
Antagonism in the human mineralocorticoid receptor.
@en
Antagonism in the human mineralocorticoid receptor.
@nl
P2093
P2860
P356
P1433
P1476
Antagonism in the human mineralocorticoid receptor
@en
P2093
Hellal-Levy C
Rafestin-Oblin ME
P2860
P304
P356
10.1093/EMBOJ/17.12.3317
P407
P577
1998-06-01T00:00:00Z